Jun 2026 (Q2 FY26) — Aug 4, 2026
Harmony Biosciences Q2 FY26 — Record WAKIX Revenue and Promising BP-205 Phase I Data
Read the full callHarmony Biosciences (HRMY) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Harmony Biosciences earnings: last reported Tue, 4 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 261 | +30.3% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | 34.2 | +10.1 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | 75.4 | +89.6% YoY | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. |
Price
$37.54 −1.08% · −$0.41
Performance +44.9% 1Y
1Y: $25.9 on 17 Oct 2025 → $37.54. High $42.86 (2 Sept 2026), low $25.9 (17 Oct 2025).
- Previous close
- $37.95
- 52-week range
- $26.02 – $42.86
- One year
- +44.27%
Overview
- Symbol
- HRMY
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
Harmony Biosciences earnings calls (HRMY)
Financials
What the filings say
Net profit, year on year: +90% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 186 | 201 | 185 | 200 | 239 | 244 | 215 | 261 |
| Operating profit | 62 | 56 | 56 | 48 | 65 | 39 | 37 | 89 |
| Operating margin | 33.2% | 27.7% | 30.4% | 24.0% | 27.4% | 15.8% | 17.3% | 34.2% |
| Interest | 4 | 4 | 4 | 4 | 4 | 4 | 3 | 3 |
| Profit before tax | 62 | 56 | 57 | 50 | 67 | 41 | 40 | 93 |
| Tax rate | 25.9% | 11.9% | 20.3% | 19.9% | 24.6% | 44.8% | 18.1% | 19.1% |
| Net profit | 46 | 49 | 46 | 40 | 51 | 22 | 32 | 75 |
| EPS ($ per share) | 0.81 | — | 0.79 | 0.69 | 0.88 | — | 0.56 | 1.30 |
| Line item | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Equity capital | — | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | -423 | -488 | -454 | -272 | -143 | 2 | 161 |
| Total liabilities | 118 | 330 | 247 | 271 | 344 | 340 | 401 |
| Fixed assets | 1 | 1 | 1 | 1 | 0 | 1 | — |
| Investments | — | — | — | 79 | 42 | 14 | 23 |
| Total assets | 107 | 427 | 433 | 674 | 811 | 999 | 1,272 |
| Line item | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Cash from operations | -75 | -3 | 99 | 144 | 219 | 220 | 348 |
| Cash from investing | -127 | -2 | -100 | -142 | -46 | -67 | -40 |
| Cash from financing | 144 | 209 | 7 | 7 | -106 | -11 | -9 |
| Net cash flow | -59 | 204 | 6 | 9 | 67 | 141 | 300 |
| Capital expenditure | -0 | -0 | -0 | -0 | -0 | -1 | -0 |
| Free cash flow | -76 | -3 | 98 | 144 | 219 | 219 | 348 |
Insider filings
43 filings between Nov 21, 2025 and Sep 18, 2026.
Open market
decisions to buy or sellPurchases
None
No insider bought shares.
Sales
$5.95M
13 sales by 3 insiders
46% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 20
- Option exercise — converted options into shares
- 10
- Tax withheld — shares kept back by the company to cover tax
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Budur Kumar | — | $3.11M | Sep 18, 2026 |
| Kapadia Sandip | — | $1.80M | Jan 26, 2026 |
| Dayno Jeffrey M. | — | $1.04M | Dec 12, 2025 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Sep 18, 2026 | Budur Kumar CHIEF MEDICAL OFFICER | Sale | 35,852 | $1.54M |
| Sep 18, 2026 | Budur Kumar CHIEF MEDICAL OFFICER | Option exercise | 25,446 | $770.3K |
| Sep 18, 2026 | Budur Kumar CHIEF MEDICAL OFFICER | Option exercise | 10,406 | $319.4K |
| Sep 17, 2026 | Budur Kumar CHIEF MEDICAL OFFICER | Sale | 800 | $34.4K |
| Sep 17, 2026 | Budur Kumar CHIEF MEDICAL OFFICER | Option exercise | 400 | $12.1K |
| Sep 17, 2026 | Budur Kumar CHIEF MEDICAL OFFICER | Option exercise | 400 | $12.3K |
| Sep 16, 2026 | Budur Kumar CHIEF MEDICAL OFFICER | Sale | 1,800 | $77.4K |
| Sep 16, 2026 | Budur Kumar CHIEF MEDICAL OFFICER | Option exercise | 900 | $27.6K |
| Sep 16, 2026 | Budur Kumar CHIEF MEDICAL OFFICER | Option exercise | 900 | $27.2K |
| Sep 8, 2026 | Budur Kumar CHIEF MEDICAL OFFICER | Option exercise | 12,200 | $374.4K |
| Sep 8, 2026 | Budur Kumar CHIEF MEDICAL OFFICER | Option exercise | 10,754 | $325.5K |
| Sep 8, 2026 | Budur Kumar CHIEF MEDICAL OFFICER | Sale | 1,000 | $42.8K |
| Sep 8, 2026 | Budur Kumar CHIEF MEDICAL OFFICER | Sale | 4,500 | $190.1K |
| Sep 8, 2026 | Budur Kumar CHIEF MEDICAL OFFICER | Sale | 22,954 | $989.3K |
| Sep 4, 2026 | Budur Kumar CHIEF MEDICAL OFFICER | Sale | 5,500 | $230.9K |
| May 1, 2026 | Budur Kumar CHIEF MEDICAL OFFICER | Option exercise | 18,750 | $0 |
| May 1, 2026 | Budur Kumar CHIEF MEDICAL OFFICER | Tax withheld | 8,882 | $282.7K |
| Apr 7, 2026 | Zaeske Adam H. CHIEF COMMERCIAL OFFICER | Tax withheld | 3,173 | $87.6K |
| Apr 7, 2026 | Zaeske Adam H. CHIEF COMMERCIAL OFFICER | Option exercise | 7,500 | $0 |
| Jan 26, 2026 | Kapadia Sandip CHIEF FINANCIAL OFFICER | Sale 10b5-1 plan | 3,746 | $139.2K |
| Jan 25, 2026 | Kapadia Sandip CHIEF FINANCIAL OFFICER | Tax withheld | 2,553 | $94.0K |
| Jan 25, 2026 | Kapadia Sandip CHIEF FINANCIAL OFFICER | Option exercise | 4,725 | $0 |
| Jan 25, 2026 | Dayno Jeffrey M. PRESIDENT, CEO | Option exercise | 13,000 | $0 |
| Jan 25, 2026 | Budur Kumar CHIEF MEDICAL OFFICER | Tax withheld | 1,372 | $50.5K |
| Jan 25, 2026 | Budur Kumar CHIEF MEDICAL OFFICER | Option exercise | 2,662 | $0 |
| Jan 25, 2026 | Dayno Jeffrey M. PRESIDENT, CEO | Tax withheld | 5,654 | $208.2K |
| Jan 25, 2026 | Serafin Andrew CHIEF STRATEGY OFFICER | Tax withheld | 1,126 | $41.5K |
| Jan 25, 2026 | Serafin Andrew CHIEF STRATEGY OFFICER | Option exercise | 2,600 | $0 |
| Jan 24, 2026 | Serafin Andrew CHIEF STRATEGY OFFICER | Tax withheld | 1,116 | $41.1K |
| Jan 24, 2026 | Serafin Andrew CHIEF STRATEGY OFFICER | Option exercise | 2,500 | $0 |
| Jan 24, 2026 | Dayno Jeffrey M. PRESIDENT, CEO | Tax withheld | 4,785 | $176.2K |
| Jan 24, 2026 | Kapadia Sandip CHIEF FINANCIAL OFFICER | Tax withheld | 2,239 | $82.4K |
| Jan 24, 2026 | Kapadia Sandip CHIEF FINANCIAL OFFICER | Option exercise | 3,813 | $0 |
| Jan 24, 2026 | Dayno Jeffrey M. PRESIDENT, CEO | Option exercise | 10,500 | $0 |
| Jan 24, 2026 | Budur Kumar CHIEF MEDICAL OFFICER | Tax withheld | 1,153 | $42.5K |
| Jan 24, 2026 | Budur Kumar CHIEF MEDICAL OFFICER | Option exercise | 2,188 | $0 |
| Jan 15, 2026 | Kapadia Sandip CHIEF FINANCIAL OFFICER | Sale 10b5-1 plan | 20,961 | $752.8K |
| Dec 12, 2025 | Dayno Jeffrey M. PRESIDENT, CEO | Sale 10b5-1 plan | 5,933 | $238.0K |
| Dec 12, 2025 | Dayno Jeffrey M. PRESIDENT, CEO | Sale 10b5-1 plan | 20,000 | $802.1K |
| Dec 12, 2025 | Dayno Jeffrey M. PRESIDENT, CEO | Option exercise 10b5-1 plan | 20,000 | $164.4K |
| Dec 5, 2025 | Kapadia Sandip CHIEF FINANCIAL OFFICER | Option exercise 10b5-1 plan | 20,000 | $580.6K |
| Dec 5, 2025 | Kapadia Sandip CHIEF FINANCIAL OFFICER | Sale 10b5-1 plan | 20,000 | $790.9K |
| Nov 21, 2025 | Kapadia Sandip CHIEF FINANCIAL OFFICER | Sale 10b5-1 plan | 3,427 | $119.9K |
| Sep 30, 2025 | Kapadia Sandip CHIEF FINANCIAL OFFICER | Tax withheld | 24,039 | $662.5K |
| Sep 30, 2025 | Kapadia Sandip CHIEF FINANCIAL OFFICER | Option exercise | 45,000 | $0 |
| Aug 28, 2025 | Valor IV Pharma Holdings, LLC 10% owner | Other | 6,618,033 | — |
| Aug 15, 2025 | Kapadia Sandip CHIEF FINANCIAL OFFICER | Sale 10b5-1 plan | 21,573 | $787.4K |
| May 1, 2025 | Budur Kumar CHIEF MEDICAL OFFICER | Option exercise | 18,750 | $0 |
| May 1, 2025 | Budur Kumar CHIEF MEDICAL OFFICER | Tax withheld | 8,869 | $264.8K |
| Apr 1, 2025 | Kapadia Sandip CHIEF FINANCIAL OFFICER | Sale 10b5-1 plan | 740 | $24.5K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for Harmony Biosciences Holdings, Inc.
Free account. Everything above stays public.
Write why you follow Harmony Biosciences Holdings, Inc. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading